BACKGROUND: Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC). METHODS: Patients with unresectable HNSCC were treated based on a previously published HxCRT regimen: 1.25 Gy twice daily to 70 Gy concurrent with cisplatin 12 mg/m(2)/day and 5-fluorouracil 600 mg/m(2)/day for 5 days, weeks 1, 5. This regimen was accelerated in this series by shortening the treatment from 7 to 6 weeks by omitting the planned mid-treatment 1-week break. RESULTS: Forty-six patients with T3-4/N3 disease were treated. The main acute toxicity was pharyngeal. Median weight change during therapy in patients with and without enteral feeding tubes was -3.8% and -7.9%, respectively (p = .08). Fifteen percent had late grade III pharyngeal toxicity. Local/regional and distant failure rates were 28% and 17%, respectively; 52% are alive without evidence of disease. CONCLUSIONS: In nonresectable HNSCC, acceleration of the HxCRT regimen is feasible, requiring enteral feeding tubes during therapy in most patients.
BACKGROUND: Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC). METHODS:Patients with unresectable HNSCC were treated based on a previously published HxCRT regimen: 1.25 Gy twice daily to 70 Gy concurrent with cisplatin 12 mg/m(2)/day and 5-fluorouracil 600 mg/m(2)/day for 5 days, weeks 1, 5. This regimen was accelerated in this series by shortening the treatment from 7 to 6 weeks by omitting the planned mid-treatment 1-week break. RESULTS: Forty-six patients with T3-4/N3 disease were treated. The main acute toxicity was pharyngeal. Median weight change during therapy in patients with and without enteral feeding tubes was -3.8% and -7.9%, respectively (p = .08). Fifteen percent had late grade III pharyngeal toxicity. Local/regional and distant failure rates were 28% and 17%, respectively; 52% are alive without evidence of disease. CONCLUSIONS: In nonresectable HNSCC, acceleration of the HxCRT regimen is feasible, requiring enteral feeding tubes during therapy in most patients.
Authors: L Miszczyk; B Maciejewski; A Tukiendorf; G Woźniak; B Jochymek; A Gawryszuk; M Szweda Journal: Br J Radiol Date: 2014-07-16 Impact factor: 3.039
Authors: Barbara Roa Pauloski; Alfred W Rademaker; Jerilyn A Logemann; Muveddet Discekici-Harris; Bharat B Mittal Journal: Head Neck Date: 2014-08-01 Impact factor: 3.147
Authors: C Orphanidou; K Biggs; M E Johnston; J R Wright; A Bowman; S J Hotte; A Esau; C Myers; V Blunt; M Lafleur; B Sheehan; M A Griffin Journal: Curr Oncol Date: 2011-08 Impact factor: 3.677
Authors: Jaime Gómez-Millán; Maria Dolores Toledo; Yolanda Lupiañez; Antonio Rueda; Jose Manuel Trigo; Antonio Sachetti; Jose Antonio Medina Journal: Clin Transl Oncol Date: 2012-08-22 Impact factor: 3.405
Authors: Aron Popovtzer; Iris Gluck; Douglas B Chepeha; Theodoros N Teknos; Jeffrey S Moyer; Mark E Prince; Carol R Bradford; Avraham Eisbruch Journal: Int J Radiat Oncol Biol Phys Date: 2009-01-08 Impact factor: 7.038
Authors: Bhavna Kumar; Arti Yadav; Nicole V Brown; Songzhu Zhao; Michael J Cipolla; Paul E Wakely; Alessandra C Schmitt; Robert A Baiocchi; Theodoros N Teknos; Matthew Old; Pawan Kumar Journal: Oncotarget Date: 2017-02-28